In Reply Unscientific prescribing constitutes 4 of 5 off-label uses,1-3 and this unscientific prescribing has resulted in a 54% increased risk of adverse drug events compared with on-label uses.2 To crack down on unscientific prescribing, drug regulatory bodies need to demand strong scientific evidence from pharmaceutical companies to safeguard the public.
Eguale T, Verma A, Tamblyn R. In Defense of Off-label Prescribing—Reply. JAMA Intern Med. 2016;176(6):861–862. doi:10.1001/jamainternmed.2016.1406
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.